| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
LUF6096 targets the adenosine A3 receptor (A3AR), functioning as an allosteric enhancer. It enhances agonist binding to the A3AR allosterically, increasing the receptor's affinity for its natural agonist, adenosine. LUF6096 shows low orthosteric affinity for any of the adenosine receptors, indicating that its effects are mediated through allosteric modulation rather than direct binding to the orthosteric site. By enhancing A3AR signaling, LUF6096 modulates immune responses, inflammation, and vascular function. The compound shows protective effects in myocardial ischemia/reperfusion injury.
|
|---|---|
| ln Vitro |
The dissociation rate of 125I-AB-MECA from A3 receptors in CHO cell membranes is halved by 2.5 times with LUF6096 (10 μM; 30-120 minutes) [1]. Forskolin-stimulated cAMP generation in CHO cells can be inhibited and the intrinsic activity of Cl-IB-MECA considerably enhanced by LUF6096 (10 μM; 15 min pretreatment) [1].
In vitro, LUF6096 is a potent allosteric enhancer of the adenosine A3 receptor. It enhances agonist binding to the A3AR allosterically while demonstrating low orthosteric affinity for any of the adenosine receptors. The compound's allosteric modulation increases the receptor's response to adenosine, potentiating A3AR-mediated signaling. In cell-based assays, LUF6096 treatment results in enhanced A3AR-mediated responses, such as inhibition of cAMP production. The compound's selectivity for A3AR over other adenosine receptors makes it a valuable tool for studying A3AR function. |
| ln Vivo |
In dogs, myocardial ischemia/reperfusion damage is prevented by LUF6096 (two intravenous bolus doses of 0.5 mg/kg or a single intravenous bolus dosage of 1 mg/kg) [1].
In vivo, LUF6096 shows protective effects in myocardial ischemia/reperfusion injury. Administration of LUF6096 (twice i.v. bolus at 0.5 mg/kg or single i.v. bolus at 1 mg/kg) protects against myocardial ischemia/reperfusion injury in dogs. The compound has been studied for its potential to modulate immune responses, inflammation, and vascular function by activating the A2B receptor. LUF6096 is particularly useful in exploring the therapeutic potential of targeting the adenosine A3 receptor for treating conditions such as asthma, inflammatory diseases, and cardiovascular disorders. |
| Enzyme Assay |
In vitro receptor binding assays for LUF6096 involve measuring its binding affinity to the adenosine A3 receptor. The receptor is incubated with a radiolabeled agonist and varying concentrations of LUF6096. The compound's allosteric enhancement is assessed by measuring the increase in agonist binding affinity in the presence of LUF6096. The compound's low orthosteric affinity is confirmed by the lack of displacement of the radiolabeled agonist. These assays confirm the compound's mechanism of action as an allosteric enhancer.
|
| Cell Assay |
In vitro cell-based assays for LUF6096 evaluate its effects on A3AR-mediated signaling. Cells expressing the adenosine A3 receptor are cultured and treated with LUF6096 in the presence or absence of an A3AR agonist. The compound's enhancement of agonist-induced signaling is assessed by measuring downstream effects such as inhibition of cAMP production, calcium mobilization, or ERK phosphorylation. These assays confirm the compound's functional activity as an allosteric enhancer.
|
| Animal Protocol |
Animal/Disease Models: Adult mongrel dogs (15-25 kg) underwent left anterior descending (LAD) coronary artery occlusion and reperfusion [1]
Doses: Two intravenous (iv) (iv)bolus injections of 0.5 mg/kg or a single intravenous (iv) (iv)bolus of 1 mg/kg given Medication: intravenous (iv) (iv)bolus Experimental Results: Infarct size was Dramatically diminished (approximately 50% reduction) compared to vehicle-treated dogs. In vivo animal experiments for LUF6096 have been conducted in a dog model of myocardial ischemia/reperfusion injury. LUF6096 (twice i.v. bolus at 0.5 mg/kg or single i.v. bolus at 1 mg/kg) protects against myocardial ischemia/reperfusion injury. The compound's effects on infarct size, cardiac function, and inflammatory markers are assessed. Pharmacokinetic studies are conducted to determine the compound's half-life, clearance, and tissue distribution. Comprehensive in vivo studies are ongoing. |
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for LUF6096 are limited. The compound has a molecular weight of 414.33 g/mol and is soluble in DMSO. For in vivo administration, LUF6096 can be administered intravenously. The compound's metabolic stability, half-life, and bioavailability have not been fully characterized. Comprehensive ADME studies are needed to fully characterize the pharmacokinetic profile of LUF6096.
|
| Toxicity/Toxicokinetics |
The toxicity profile of LUF6096 has not been extensively characterized. In laboratory settings, LUF6096 should be handled as a hazardous chemical. Appropriate personal protective equipment should be used when handling the compound. The compound is for research use only and is not intended for human or veterinary use. Comprehensive toxicological studies are needed to fully characterize the safety profile of LUF6096.
|
| References |
[1]. Heitman LH, et, al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. J Med Chem. 2009 Feb 26;52(4):926-31.
[2]. Du L, et, al. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. |
| Additional Infomation |
LUF6096 (CF-602) is a potent allosteric enhancer of the adenosine A3 receptor (A3AR). It has a molecular formula of C₂₂H₂₁Cl₂N₃O and a molecular weight of 414.33 g/mol. LUF6096 enhances agonist binding to the A3AR allosterically while demonstrating low orthosteric affinity for any of the adenosine receptors. The compound shows protective effects in myocardial ischemia/reperfusion injury. LUF6096 is useful for studying A3AR function and therapeutic potential.
|
| Molecular Formula |
C22H21CL2N3O
|
|---|---|
| Molecular Weight |
414.33
|
| Exact Mass |
413.106
|
| CAS # |
1116652-18-6
|
| Related CAS # |
1116652-18-6;
|
| PubChem CID |
25191023
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.875
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
528
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC=1C=CC(=CC1Cl)N=C2NC3=CC=CC=C3C(=C2)NC(C4CCCCC4)=O
|
| InChi Key |
UWEIQVQNNLVOEI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21Cl2N3O/c23-17-11-10-15(12-18(17)24)25-21-13-20(16-8-4-5-9-19(16)26-21)27-22(28)14-6-2-1-3-7-14/h4-5,8-14H,1-3,6-7H2,(H2,25,26,27,28)
|
| Chemical Name |
N-[2-[(3,4-Dichlorophenyl)amino]-4-quinolinyl]-cyclohexanecarboxamide
|
| Synonyms |
LUF6096 LUF 6096LUF-6096CF-602 CF602 CF 602
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~48.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4135 mL | 12.0677 mL | 24.1354 mL | |
| 5 mM | 0.4827 mL | 2.4135 mL | 4.8271 mL | |
| 10 mM | 0.2414 mL | 1.2068 mL | 2.4135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
